research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
Search
for
Sort by
Research
180-210 / 1000+ results
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Safety and Efficacy of an Oral Nutraceutical Supplement Gummy and Peptide Serum in Promoting Hair Growth: Initial Results of A Randomized Placebo Controlled Trial with an Open Label Extension
The supplement gummy and serum safely improve hair growth in women with hair loss.
research In vivo anti-<b><i>Trichophyton</i></b> Activities of Seed Oil Obtained from <b><i>Caragana</i></b><b><i>korshinskii</i></b> Kom.
Caragana korshinskii seed oil effectively treats fungal skin infections.
research Topical gabapentin and its relation to cutaneous innervation in symptomatic lymphocytic primary cicatricial alopecia
Using a special skin cream with gabapentin helped reduce symptoms of a certain scalp condition but didn't change nerve fibers or skin chemicals.
research Dermatology life quality index in patients with persisting and recurrent dermatophytoses
Fungal skin infections significantly lower patients' quality of life.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Effect of Hataedock Treatment on Epidermal Structure Maintenance through Intervention in the Endocannabinoid System
Hataedock treatment improved skin health and reduced atopic dermatitis symptoms by enhancing the skin barrier and reducing inflammation.
research Niosomes as a propitious carrier for topical drug delivery
Niosomes are promising for skin drug delivery, offering benefits like improved drug penetration and stability.
research The Efficacy of Platelet‐Rich Plasma in Facial Lichen Planus Pigmentosus: A Prospective Pilot Study
PRP treatment improved skin pigmentation and appearance in facial lichen planus pigmentosus.
research Genital Dermatology
Different skin conditions show distinct types of vessel inflammation, a new quality of life index for vulval disease is reliable, a certain intrauterine system might be linked to chronic vaginal yeast infections, and oral minoxidil reduces hair loss in women.
research TOXIC EPIDERMAL NECROLYSIS
Toxic epidermal necrolysis is a severe skin reaction often linked to drugs, requiring careful medication use and supportive care.
research Evidence for Novel Functions of the Keratin Tail Emerging from a Mutation Causing Ichthyosis Hystrix
The keratin tail is crucial for skin structure and function.
research Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
research Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints
Mesenchymal stem cells may effectively treat and prevent allergic skin conditions.
research A cosmetic formulation improves facial erythema in vivo
A new cosmetic cream reduced facial redness and skin temperature after 4 weeks of use.
research DNA Methyltransferases in Malar Melasma and Their Modification by Sunscreen in Combination with 4% Niacinamide, 0.05% Retinoic Acid, or Placebo
Treatments with sunscreen and active ingredients can reduce skin hyperpigmentation by decreasing DNA methylation.
research Low-level light-assisted photodynamic therapy using a wearable cap-like device for the treatment of actinic keratosis of the scalp
A wearable cap-like device using light therapy reduced scalp skin lesions by 71% and was painless.
research Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair
Eflornithine HCl 13.9% cream is safe for skin use with mild, temporary irritation.